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SODIUM AND BLOOD PRESSURE
Effects of Within-Person Variability in Spot 
Urinary Sodium Measurements on Associations 
With Blood Pressure and Cardiovascular Disease
Federica Re , Imen Hammami, Thomas J. Littlejohns, Matthew Arnold, Sarah Lewington ,* Robert J. Clarke ,* Jennifer L. Carter *
ABSTRACT: Randomized trials of salt restriction have consistently demonstrated that decreasing salt consumption lowers blood 
pressure, but results of observational studies of salt intake and cardiovascular disease have been conflicting. After excluding 
individuals with prevalent cardiovascular or kidney disease in the prospective UK Biobank study, we examined the within-
person variability in spot urinary sodium excretion and its impact on associations with systolic blood pressure and risk of 
incident cardiovascular disease. Spearman correlation coefficients were used to assess within-person variability in spot urinary 
sodium, and associations between sodium and blood pressure were assessed using linear regression in participants with 
measurements at baseline (N=355 134) and after 9 years (N=33 915). Cox regression was used to assess associations with 
the risk of cardiovascular disease over the same follow-up period (N=5566 events). The within-person variability in urinary 
sodium was extreme, with a self-correlation coefficient of 0.35 over 4 years. Each 100 mmol/L higher usual urinary sodium 
was associated with 3.09 mm Hg higher systolic blood pressure (95% CI, 2.7–3.48) at baseline, but had no association 
at 9 years (0.97 [−0.44 to 2.37]). Likewise, there was no association between urinary sodium and risk of cardiovascular 
disease over the same follow-up period (hazard ratio, 1.05, [0.87–1.26]). While spot urinary sodium measurements were 
associated with immediate effects on blood pressure at baseline, the extreme within-person variability in urinary sodium 
precluded detection of associations with future blood pressure at resurvey or risk of cardiovascular disease. The limitations 
of observational studies, irrespective of study size, should be recognized when assessing public policy on salt restriction. 
(Hypertension. 2021;78:1628–1636. DOI: 10.1161/HYPERTENSIONAHA.120.16549.) • Data Supplement
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Higher levels of blood pressure are associated with higher risks of stroke and ischemic heart disease, with a 20 mm Hg higher systolic blood pressure (SBP) 
being associated with an ≈2-fold higher risks of death from 
cardiovascular disease (CVD) outcomes.1 Elevated blood 
pressure accounts for almost half of all deaths from CVD 
worldwide.2,3 Randomized trials have consistently demon-
strated that restriction of dietary salt intake (dietary sodium) 
lowers blood pressure, prompting the World Health Organi-
zation to recommend limiting dietary sodium intake to <2.3 
g/d (equivalent to 6 g/d of salt).4–6 However, several pro-
spective cohort studies have recently reported that intakes 
of dietary sodium <4 g/d were associated with higher risks 
of CVD mortality, and these results were used to challenge 
the validity of the World Health Organization’s recommen-
dations on salt restriction for prevention of CVD.7–10
See Editorial, pp 1637–1639
The reasons for the discrepant results between the 
beneficial associations of salt restriction on levels of 
blood pressure observed in randomized trials, and the 
apparent null or possible hazardous associations of low 
intakes of dietary salt with risks of CVD observed in 
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prospective cohort studies remain unexplained.6–9 The 
aims of the present study were to use the large prospec-
tive UK Biobank study to: (1) examine the magnitude 
of within-person variability in spot measurements of uri-
nary sodium (UNa); (2) assess associations of UNa with 
mean levels of SBP at baseline and at resurvey 9 years 
later, and (3) examine associations of UNa with the risk 
of incident CVD events during the same follow-up period.
METHODS
All results from this analysis are returned to UK Biobank within 
6 months of publication, at which point they can be made 
available to other researchers upon reasonable request. UK 
Biobank is an open access resource, and researchers can apply 
to use the data set at http://ukbiobank.ac.uk/register-apply/.
Study Population
This study used data from 502 619 men and women in the UK 
Biobank who were aged 40 to 69 years at recruitment between 
2006 and 2010.11 Participants were invited to attend one of 
22 baseline assessment centers within 25 miles of 22 major 
cites located throughout England, Scotland, or Wales. Data were 
collected on sociodemographic, lifestyle, and health-related 
characteristics using an electronic touchscreen questionnaire. 
All participants had their blood pressure and anthropometry 
recorded, and blood and urine samples were collected for 
long-term storage. Repeat measurements of all assessments, 
including urine samples, were collected on a sample of 20 346 
participants at 4 years after baseline (2012–2013), and repeat 
questionnaires and blood pressure measurements were also 
recorded in 33 915 participants at 9 years after baseline (2016–
2019). See Figure S1 in the Data Supplement for a flowchart 
of measurements used in the present analyses. Ethical approval 
was obtained from the North-West Multi-Centre Research 
Ethics Committee (REC reference: 11/NW/03820) and all 
participants provided written informed consent.
Measurement of UNa
During both the baseline assessment and resurvey visit at 4 
years after baseline, nonfasting spot urine samples were col-
lected from all participants. Samples were transferred from the 
collection vessels to vacutainers and stored at 4 °C in tempera-
ture-controlled boxes before overnight shipment to the coordi-
nating centre laboratory for long-term storage.12 Urine analyses 
were performed at 24 to 36 hours after sample collection using 
a Beckman Coulter AU5400.12
UNa excretion in spot urine samples was primarily mea-
sured as crude UNa values (mmol/L). Since spot UNa samples 
are confounded by diurnal variation, in addition to dilution by 
urine volume,13 measures of spot UNa were standardized to 
urinary creatinine concentrations using the INTERSALT equa-
tion to estimate 24-hour excretion of UNa (g/d; Methods S1). 
This formula takes account of spot creatinine concentrations, 
spot potassium excretion, age, sex, and body mass index (BMI) 
measurements. Hence, it should be less affected by diurnal and 
other sources of within-person variation.14,15 Since the valida-
tion of the INTERSALT equation is only moderate (which is 
the case for all 24-hour estimating equations), the results are 
reported alongside the estimates for crude UNa values; results 
using the Kawasaki equation of estimated 24-hour excretion 
(which are presented for comparison with previous research) 
are reported in the supplement since this equation was not vali-
dated for the type of urine sample in UK Biobank.14,16,17
Measurement of Blood Pressure
Blood pressure was measured twice using an Omron HEM-
7015IT digital sphygmomanometer after participants had been 
in the seated position for at least 5 minutes.18 Measurements 
were recorded manually by trained staff for participants in whom 
blood pressure could not be measured electronically. The mean 
levels of both measurements of SBP were used in the analysis.
Novelty and Significance
What Is New?
• The within-person variability of spot urinary sodium 
measurements in the large prospective UK Biobank is 
extreme.
• There was a linear positive association between uri-
nary sodium and immediate systolic blood pressure, 
but no association between sodium and prospective 
blood pressure or incident cardiovascular disease.
What Is Relevant?
• Spot measurements of urinary sodium excretion were 
positively associated with immediate effects on systolic 
blood pressure, but the magnitude of within-person 
variability in urinary sodium excretion was so extreme 
as to preclude any possibility of detecting associations 
with future systolic blood pressure or incident cardio-
vascular disease.
Summary
Failure to appreciate the effects of within-person vari-
ability in prospective cohort studies, irrespective of the 
study size, can lead to erroneous claims about hazards 
or a lack of benefit.
Nonstandard Abbreviations and Acronyms
BMI body mass index
CVD cardiovascular disease
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Ascertainment of Incident CVD
Incident CVD events were recorded by linkage with hospi-
tal inpatient records from the Hospital Episode Statistics for 
England (1996 onwards), the Scottish Morbidity Record (1981 
onwards), and the Patient Episode Database for Wales (1998 
onwards). Incident CVD was defined as hospital admission for 
a primary or secondary diagnosis of nonfatal or death from 
myocardial infarction or stroke (ICD-10 codes I2I-I23, 124.1, 
I25.2, and I60-I64 [excluding I62]). Censoring dates were 31st 
October 2016 for Scotland; 29th February 2016 for Wales; and 
31st March 2017 for England.
Statistical Analyses
Cross-Sectional Analyses
To examine the convergent validity of associations between 
crude UNa excretion (mmol/L) and self-reported dietary intake 
of foods high in sodium or potassium at baseline, sex- and age-
adjusted means of crude UNa levels were compared across 
the frequency of adding salt to food (from never to always), 
consuming processed meat (from never to almost daily), and 
intake of fruit and vegetables (quartiles of usual daily portions). 
Spearman correlations were estimated between UNa and ordi-
nal categories of food intake.
To assess within-person variability in the baseline measures 
of UNa, in addition to relevant covariates (Table S2), Spearman 
correlation coefficients between repeat measurements at 
baseline and at 4 years after baseline were estimated in a 
sample of participants with repeat measurements (N=20 346). 
To estimate the reproducibility of 24-hour sodium excretion 
independent of the reproducibility of covariates included in the 
INTERSALT estimating equation, repeat 24-hour UNa mea-
surements were regressed on baseline 24-hour UNa, after 
adjustment for age, sex, BMI, potassium, and creatinine.
Multivariable linear regression was used to estimate 
cross-sectional associations of UNa with mean levels of 
SBP measured at baseline. The effects of possible con-
founding factors were assessed by comparing the differ-
ences in the F test values (which are reported as χ2 values 
due to their equivalence for a large population size and for 
ease of interpretation) for UNa across different models. The 
baseline model 1 adjusted for age and sex. Model 2 included 
adjustment for sociodemographic factors and health behav-
iours (see Methods S2 for details: ethnicity; family history 
of hypertension; season; time of day of urine sample; usual 
fluid consumption; education; Townsend index of deprivation; 
smoking; alcohol intake, physical activity; and exogenous hor-
mones).19–21 Model 3 additionally adjusted for the spot urinary 
potassium/creatinine ratio.21 Finally, model 4 also adjusted 
for BMI (height/weight [kg/m2]). The same adjustments 
were also used when assessing associations with estimated 
24-hour UNa using the INTERSALT equation.
To ensure the results of the cross-sectional and prospective 
associations between UNa and SBP were not due to different 
sample sizes, a sensitivity analysis examined the cross-sectional 
analyses when restricted to those that had SBP measurements 
at both baseline and at resurvey (N=33 915; Figure S3).
Prospective Analyses
The association of baseline UNa with SBP measured at a 
resurvey 9 years after baseline (future SBP) was estimated 
using multivariable linear regression with adjustment for the 
same confounders outlined above. Since the association of 
UNa with the risk of incident CVD is mediated by the associa-
tion with blood pressure, the association of UNa with CVD was 
estimated for a similar follow-up period as those with a resur-
vey of SBP measurements.22 Cox regression was used for 
analyses of associations with CVD, where the follow-up was 
calculated until the first CVD event after recruitment, death, 
or otherwise censored. Models were stratified by 5-year age 
bands at recruitment and were adjusted for the confounders 
outlined above.
Since the strength of the associations of baseline UNa 
with SBP and CVD are likely to be weaker than the asso-
ciations of usual (ie, long-term average) levels of UNa, all 
analyses were corrected for regression dilution using previ-
ously reported methods.23,24 Participants were first ranked 
into groups of UNa at baseline (quintiles, with the lowest 
quintile of UNa divided further into tertiles for more detail), 
and the mean values of UNa at resurvey in those baseline 
defined groups (ie, the usual values) were used when plotting 
results. Assuming the associations were linear, analyses for 
100 mmol/L higher usual crude UNa (and for 1 g/d higher 
usual 24-hour INTERSALT UNa) were estimated by dividing 
the β coefficient and their standard errors by the regression 
dilution ratio obtained between baseline and resurvey UNa.23 
These adjustments should correct for attenuation due to 
random error, but they will not affect systematic errors in 
measurements of UNa. Further sensitivity analyses checked 
the associations of SBP measured at baseline with the risk 
of CVD (Figure S5).
Patient and Public Involvement
Participants were not involved in formulation of any research 
questions or outcome measures used in the present report, but 
were consulted about the ethics and governance frameworks, 
and engaged in periodic reviews of UK Biobank using follow-




Analyses excluded participants with missing data on 
UNa (N=16 518), SBP (N=412), BMI (N=1227), 
and other covariates (N=3685). To limit the effects of 
reverse causality, analyses excluded participants with 
a history of prior CVD (N=33 301), kidney disease 
(N=3017), macroalbuminuria (N=1552), or diabetes 
(N=20 962) at baseline; CVD events occurring dur-
ing the first 2 years of follow-up were also dropped 
(N=1044). Participants reporting use of antihyperten-
sive medication at baseline were also excluded to limit 
reverse causality (N=66 811). For participants that 
began taking blood pressure-lowering medication after 
baseline (and after the measurement of UNa; N=4102; 
12.1%), a constant of 10 mm Hg was added to future 
SBP values.26,27 The main analyses were based on 
355 134 participants (70.7% of the original sample), 
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including 33 915 participants who had SBP measure-
ments recorded at both baseline and resurvey.
The mean age of the study participants was 55.2 
years (SD, 8.1), 4.7% were from a non-White ethnic-
ity, and 42.8% were men (Table 1). Mean (SD) levels at 
baseline of SBP were 135.9 (18.4) mm Hg and diastolic 
blood pressure were 81.8 (10.1) mm Hg, and the mean 
levels at resurvey 9 years later were 139.0 (19.2) and 
78.6 (10.0) mm Hg, respectively. Mean (SD) levels of 
UNa were 76.4 (44.3) mmol/L and increased from an 
average of 26.7 (6.9) to 147.0 (29.5) mmol/L (and from 
2.3 [0.2] to 4.4 [0.4] g/d in estimated 24-hour UNa, 
Table S1) between the lowest and highest quintiles. The 
highest quintile of UNa excretion had a higher percent-
age of participants that were male, non-White, current 
smokers, with lower education, and higher BMI.
Estimates of within-person variability between 
baseline and resurvey UNa were extreme, with self-
correlations (ρ) of 0.35 for crude UNa and, after 
adjustment for covariates in the estimating equation, 
0.32 for the INTERSALT 24-hour UNa (g/d; ρ=0.80 
before adjustment for covariates). For covariates, esti-
mates of within-person variability were low for BMI 
(ρ=0.92), but moderate for physical activity (0.55) 
and high for urinary potassium (0.26; Table S2). There 
was a strong confounding effect of sex, but since 
heterogeneity by sex was neither significant nor sub-
stantive, the sex-specific associations are presented 
in Table S3 and Figure S4.
Cross-Sectional Associations
Analyses of age- and sex-adjusted crude UNa levels 
with self-reported dietary intake demonstrated linear 
associations between higher levels of UNa with higher 
intakes of processed meat or added salt, and an inverse 
association with fruit and vegetable consumption (Fig-
ure 1). However, despite the apparent associations 
between these markers of sodium/potassium intake 
and UNa, correlations between the variables were low 
(ρ=0.12 [added salt], ρ=0.18 [processed meat], and 
ρ=−0.19 [fruit/veg]).
In baseline models adjusted for age and sex, mean 
levels of immediate SBP increased by an average 
of 8.2 mm Hg (95% CI, 7.8–8.5, P<0.001) for each 
100 mmol/L higher usual UNa (Figure 2). Sequential 
adjustment for confounders showed that adjustment 
for sociodemographic and health-related behaviours 
(model 2) accounted for 18% of the association (χ2: 
1796 versus 1465). Adjustment for potassium mar-
ginally attenuated the association, but adjustment 
for BMI explained 80% of the remaining association 
Table. Characteristics of UK Biobank Participants Overall and by Quintile of Crude Urinary Sodium Excretion (mmol/L)
Characteristics
 Quintiles of crude urinary sodium excretion, mmol/L
Overall Lowest Q2 Q3 Q4 Highest
Sodium, mmol/L 76.4 (44.3) 26.7 (6.9) 46.7 (5.5) 67.5 (6.6) 94.7 (9.4) 147.0 (29.5)
Socio-demographics
 Age, y 55.2 (8.1) 56.0 (7.8) 56.1 (7.9) 55.7 (8.1) 55.1 (8.1) 53.2 (8.1)
 Male, n (%) 152 169 (42.8) 17 706 (24.9) 24 896 (35.0) 30 124 (42.5) 36 017 (50.7) 43 426 (61.3)
 Non-White ethnicity, n (%) 16894 (4.7) 1910 (2.7) 2318 (3.3) 2962 (4.2) 3750 (5.3) 5954 (8.4)
 High education, n (%) 124 866 (35.2) 28 417 (39.9) 26 397 (37.1) 24 901 (35.1) 23 849 (33.6) 21 302 (30.1)
 Townsend index −1.4 (3.0) −1.7 (2.9) −1.7 (2.9) −1.5 (2.9) −1.4 (3.0) −0.9 (3.3)
Health behaviours
 High alcohol intake, n (%) 48 250 (13.6) 7417 (10.4) 8291 (11.7) 9379 (13.2) 10 995 (15.5) 12 168 (17.2)
 Current smoking, n (%) 37 671 (10.6) 6324 (8.9) 6676 (9.4) 7061 (10.0) 8014 (11.3) 9596 (13.5)
 High physical activity, n (%) 99 536 (28.0) 19 488 (27.4) 19 306 (27.1) 19 366 (27.3) 20 012 (28.2) 21 364 (30.1)
Anthropometry
 Weight, kg 76.1 (15.0) 70.8 (13.0) 73.5 (13.7) 75.9 (14.9) 78.6 (15.2) 81.9 (15.9)
 Body mass index, kg/m2 26.7 (4.4) 25.5 (4.0) 26.1 (4.0) 26.7 (4.2) 27.3 (4.5) 28.1 (4.7)
 Immediate SBP, mm Hg 135.9 (18.4) 133.9 (18.4) 135.7 (18.5) 136.1 (18.5) 136.6 (18.2) 137.4 (18.1)
 Immediate DBP, mm Hg 81.8 (10.1) 80.4 (9.9) 81.2 (9.9) 81.7 (10.0) 82.3 (10.1) 83.3 (10.2)
 Future SBP, mm Hg 139.0 (19.2) 137.3 (19.5) 138.7 (19.6) 139.3 (19.4) 139.9 (18.7) 140.0 (18.7)
 Future DBP, mm Hg 78.6 (10.0) 77.4 (10.0) 78.0 (10.1) 78.7 (9.9) 79.2 (9.9) 80.0 (10.0)
Urinary biomarkers
 Potassium, mmol/L 63.1 (34.2) 41.2 (27.0) 52.8 (30.6) 64.9 (33.2) 75.5 (33.0) 81.1 (30.1)
 Creatinine, mmol/L 8757.5 (5741.0) 4700.0 (4160.0) 6502.1 (4672.5) 8663.1 (5219.2) 10 926.5 (5340.9) 13 018.3 (5049.2)
Usually adds salt to food, n (%) 17 261 (4.9) 2163 (3.0) 2744 (3.9) 3182 (4.5) 3707 (5.2) 5465 (7.7)
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between UNa and SBP (χ2: 1190 versus 243). After 
full adjustment, immediate SBP was an average of 
3.1 (95% CI, 2.7–3.5, P<0.001) mm Hg higher for 
each 100 mmol/L higher usual UNa, with a linear 
positive association across the range of UNa values 
studied (Figure 3A). The association with immedi-
ate SBP was slightly weaker, but broadly equivalent, 
when the sample was restricted to the subset of 
participants with data on SBP from both surveys 
(N=33 915; Figure S3).
Prospective Analyses
The associations of baseline UNa with future SBP 
measured an average of 9 years later were only half as 
strong in the minimally adjusted models for age and sex 
compared with those in the cross-sectional analyses 
(χ2: 65 versus 124; Figure S3) and were no longer sig-
nificant after full adjustment for covariates (0.97 mm Hg 
[95% CI, −0.44 to 2.40], P=0.18; Figure 2; Figure 3B). 
Despite a stronger positive linear association between 
each 1 g/d higher 24-hour usual UNa (INTERSALT) 
and immediate SBP than was reported for crude UNa 
and immediate SBP (4.3 versus 3.1 mm Hg), there was 
likewise no remaining association between 24-hour 
UNa (INTERSALT) and future SBP (−0.07 mm Hg 
[−0.7 to 0.5]; Figure 2; Figure 3B).
The analysis of baseline UNa with incident CVD 
involved 5566 events occurring during an average 
of 7.9 years of follow-up. There was no association 
between a 100 mmol/L higher usual UNa excre-
tion with risk of CVD (HR, 1.05 [95% CI, 0.87−1.26], 
P=0.55, Figure 3C), nor with 24-hour usual UNa 
(INTERSALT, HR, 0.99 [95% CI, 0.92−1.06], P=0.76).
Lastly, sensitivity analyses confirmed that the associa-
tion of SBP with risk of CVD in this cohort was linear and 
positive as expected (Figure S5).
DISCUSSION
The present study demonstrated linear positive associa-
tions of higher levels of UNa excretion with immediate 
SBP but not between baseline UNa values and future 
SBP recorded at 9 years after baseline. Since SBP is the 
chief mechanism through which UNa is likely to affect 
CVD, the lack of association between baseline UNa and 
future SBP suggested that no association was likely to 
be detected with incident CVD over the corresponding 
follow-up period, as observed in the present analyses.22
Several hypotheses have been suggested to explain 
the discrepant results between the beneficial effects 
observed in randomized trials of sodium restriction on 
blood pressure, and the higher risks of CVD associated 
with low sodium intake in prospective studies. The pres-
ent study demonstrated positive associations between 
UNa and immediate blood pressure but no association 
between sodium and subsequent SBP or incident CVD. 
One potential explanation is that there is an adverse 
effect of low sodium intake on CVD, which may coun-
teract any beneficial effect of low UNa on SBP, such as 
the activation of the renin-angiotensin-aldosterone sys-
tem.10 However, one meta-analysis reported no effects of 
sodium restriction on catecholamine levels,5 and another 
study reported only modest increases in plasma renin 
activity, aldosterone, and noradrenaline that would likely 
attenuate over a longer duration of follow-up.28,29
An alternative explanation for the discrepant effects 
reported between the randomized trials and obser-
vational studies is the contrasting methods used for 
Figure 1. Mean levels of urinary 
sodium (mmol/L) by levels of self-
reported dietary intake (adjusted for 
age and sex; N=355 134).
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measurement of sodium intake. Randomized trials, which 
typically involve a much smaller number of participants, 
frequently use gold standard multiple 24-hour urine col-
lections to estimate UNa and hence sodium intake.30 
However, use of such methods is not feasible in large 
observational studies, where it is only feasible to collect 
single spot or timed urine collections (which are then 
used to estimate 24-hour UNa using algorithms with 
spot creatinine excretion). While some validation studies 
have downplayed biases inherent in spot measurements, 
the impact of validation estimates in the range of 0.30 
to 0.50 cannot be underestimated.31 Previous validation 
studies have reported that >50% of individuals would be 
misclassified when ranking participants by estimates of 
24-hour UNa.17,32–34 One study demonstrated the effect 
of this error by comparing associations with incident CVD 
and mortality from a single baseline measurement of 
24-hour sodium versus the average of multiple 24-hour 
sodium measurements over 5 years.35 No association 
was documented when a single measurement was used, 
but the use of multiple 24-hour measurements demon-
strated that over 50% of participants moved tertiles of 
sodium intake, and positive associations with incident 
disease were up to 85% stronger.35 In the present study, 
correlations between spot UNa measurements and 
self-reported intake of foods high in sodium were low, 
suggesting low convergent validity between rankings 
of participants. The potential impact of such substan-
tial measurement error in spot UNa measurements was 
demonstrated in the present study as the associations 
of baseline UNa with immediate SBP were completely 
attenuated when associations with repeat measure-
ments of SBP were examined at a resurvey 9 years 
after baseline. If the strong, positive, and linear associa-
tions with blood pressure (as consistently demonstrated 
by randomized trials)28 are obscured by high levels of 
within-person variability in spot UNa measurements, it is 
unlikely that any risk of CVD could be detected over the 
corresponding follow-up period.
Results of observational studies of UNa also need 
to consider the potential impact of using algorithms to 
estimate 24-hour UNa from single spot urine measure-
ments. The most widely used estimation equations rely 
on the assumption that the ratio of spot sodium to spot 
creatinine is equivalent over a 24-hour period.14,36 First, 
the assumption of a constant ratio between spot sodium 
and creatinine and 24-hour measurements is prob-
lematic, especially as spot creatinine excretion can be 
Figure 2. Associations of usual 
urinary sodium (UNa) with immediate 
(N=355 134) and future systolic blood 
pressure (SBP; N=33 915) before and 
after adjustment for confounding 
factors.
+ ethnicity, family history, time of sample, 
season of sample, fluids, education, 
Townsend index, smoking, alcohol 
intake, physical activity, and hormone 
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influenced by confounders such as recent protein intake 
and exercise.14,36 Second, the incorporation of age, sex 
and BMI into the estimation of UNa may result in spuri-
ous correlations since each of these variables has their 
own relationship with both sodium intake and CVD.37 This 
may explain why, in the present study, the association of 
estimated 24-hour UNa excretion with the INTERSALT 
equation and mean levels of SBP at baseline was much 
stronger than those using crude UNa values. However, 
analyses of the reproducibility of both INTERSALT and 
crude UNa were concordant after inclusion of the covari-
ates in the estimating equation. Hence, despite the stron-
ger associations reported between estimated 24-hour 
UNa excretion (INTERSALT) and immediate SBP, asso-
ciations between baseline 24-hour UNa and future SBP 
were still completely attenuated, and there was no overall 
association with incident CVD.
Lastly, observational studies assessing associations 
between low sodium intake and CVD risk should also 
consider the possible effects of confounding factors aris-
ing from the comparison of different populations using 
an ecological study design or reverse causality in individ-
uals at high-risk of CVD, where subclinical or prevalent 
disease leads to a change in either sodium intake or 
excretion.29,38 The large international PURE Study (Pro-
spective Urban Rural Epidemiological) cohort was con-
strained by both limitations, which could account for their 
reported J-shaped associations between sodium excre-
tion and CVD.10 In contrast, recent prospective analyses 
of UNa and risk of CVD in UK Biobank, which included 
more rigorous control for prior disease and studied a 
more homogenous population, found no association 
between low UNa and higher risks of CVD.16,39
Strengths and Limitations
The present study involving a large population-based 
cohort provided a reliable assessment of the shape of 
the association of UNa excretion with SBP and with 
risk of CVD, even when the lowest quintile of sodium 
was further divided into tertiles. Strategies to reduce 
the effects of reverse causality bias involved excluding 
participants whose sodium intake or excretion may have 
been affected by a diagnosis of disease, such as those 
with self-reported CVD events before baseline assess-
ment or use of antihypertensive medication. However, 
Figure 3. Associations of usual urinary sodium (UNa) with immediate systolic blood pressure (SBP), future SBP, and risk of 
cardiovascular disease (CVD) after adjustment for confounding factors (as per Figure 2).
HR indicates hazard ratio.
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antihypertensive medication may also be on the causal 
pathway relating sodium intake to SBP, so this restric-
tion may have attenuated the reported associations. 
Alternatively, including such participants in the analysis 
could have biased the associations depending on how 
such medication affected sodium excretion, or if par-
ticipants had changed their sodium intake as part of 
dietary advice following a diagnosis of hypertension. A 
wide range of variables that may have confounded these 
analyses were adjusted for, but there may still be resid-
ual confounding due to unmeasured confounders (eg, 
total energy intake) and in self-reported confounders 
which are prone to reporting biases (eg, physical activ-
ity, smoking, and medications). Considering the analysis 
of within-person variability, adjustment for confounders 
measured with much higher reproducibility than sodium, 
such as BMI, may have contributed to why this variable 
explained so much of the association in Figure 2. Con-
versely, adjustment for confounders with lower reproduc-
ibility could have led to further residual confounding as a 
result of not adjusting for their usual values. As such, the 
associations reported in this study are not considered to 
be causal. Lastly, the study corrected for regression dilu-
tion bias arising from random error, but validation stud-
ies have also reported potential systematic errors in spot 
UNa measurements, which could bias associations with 
disease in any direction.17,33
Perspectives
Prospective observational studies of UNa and risk of 
CVD have been used to challenge public health advice 
on restriction of salt intake to lower SBP and prevent 
CVD. While the limitations of measurements of dietary 
sodium intake have been widely reported, few studies 
have appreciated the magnitude of both measurement 
error and within-person variability in spot measurements 
of UNa, and their impact on associations with CVD out-
comes. The present study demonstrated that the mag-
nitude of within-person variability of spot UNa was so 
extreme that it completely attenuated any potential pro-
spective associations with blood pressure. In contrast, 
meta-analyses of randomized trials have consistently 
demonstrated that sodium restriction lowers blood pres-
sure.40 Despite some claims of a potential J-shaped 
association of CVD at lower levels of sodium intake, the 
recent 2019 review of Dietary Reference Intake Values 
for sodium by the National Academies of Sciences, Engi-
neering, and Medicine in the United States and Can-
ada has continued to advocate that adults reduce their 
sodium intake to 2.3 g/d based on worldwide evidence 
on this topic, particularly from evidence of randomized 
trials.41 It is important to recognize the limitations of 
observational studies, irrespective of their study size, and 
the importance of within-person variability in prospective 
studies. Failure to account for such biases can obscure 
true associations of dietary salt restriction on levels of 
blood pressure and the risk of CVD. Public health rec-
ommendations need to be guided by randomized trials 
of sodium restriction rather than relying on observational 
studies to address such questions.
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